Free Trial

Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these companies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consistently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Immunic stock logo

1. Immunic NASDAQ:IMUX

$0.97 +0.01 (+1.34%)
As of 05/20/2025 04:00 PM Eastern

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about Immunic

Market Capitalization
$93.29 million
P/E Ratio
-0.79
Consensus Rating
Buy
Consensus Price Target
$13.20 (+1,255.8% Upside)
Volume
394,652 shares
Average Volume
715,245 shares
Stardust Power stock logo

2. Stardust Power NASDAQ:SDST

$0.61 +0.05 (+9.67%)
As of 05/20/2025 04:00 PM Eastern

Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.

Market Capitalization
$35.13 million
P/E Ratio
-0.82
Consensus Rating
Buy
Consensus Price Target
$5.11 (+742.7% Upside)
Volume
755,179 shares
Average Volume
404,579 shares
Context Therapeutics stock logo

3. Context Therapeutics NASDAQ:CNTX

$0.68 -0.03 (-3.89%)
As of 05/20/2025 04:00 PM Eastern

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context Therapeutics

Market Capitalization
$60.89 million
P/E Ratio
-0.75
Consensus Rating
Buy
Consensus Price Target
$6.00 (+783.9% Upside)
Volume
177,934 shares
Average Volume
286,175 shares
FibroBiologics stock logo

4. FibroBiologics NASDAQ:FBLG

$0.91 +0.00 (+0.27%)
As of 05/20/2025 04:00 PM Eastern

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologics

Market Capitalization
$34.95 million
P/E Ratio
-4.35
Consensus Rating
Buy
Consensus Price Target
$13.00 (+1,323.3% Upside)
Volume
123,025 shares
Average Volume
298,541 shares
Rani Therapeutics stock logo

5. Rani Therapeutics NASDAQ:RANI

$0.75 +0.05 (+7.01%)
As of 05/20/2025 04:00 PM Eastern

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani Therapeutics

Market Capitalization
$40.24 million
P/E Ratio
-0.71
Consensus Rating
Buy
Consensus Price Target
$9.40 (+1,154.8% Upside)
Volume
407,052 shares
Average Volume
797,445 shares
Ur-Energy stock logo

6. Ur-Energy NYSEAMERICAN:URG

$0.70 +0.02 (+2.83%)
As of 05/20/2025 04:10 PM Eastern

Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur-Energy

Market Capitalization
$256.62 million
P/E Ratio
-5.42
Consensus Rating
Buy
Consensus Price Target
$2.30 (+226.3% Upside)
Volume
2.41 million shares
Average Volume
4.14 million shares
Lineage Cell Therapeutics stock logo

7. Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$0.49 -0.01 (-2.37%)
As of 05/20/2025 04:10 PM Eastern

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More about Lineage Cell Therapeutics

Market Capitalization
$107.04 million
P/E Ratio
-4.05
Consensus Rating
Buy
Consensus Price Target
$4.20 (+764.9% Upside)
Volume
896,136 shares
Average Volume
1.30 million shares
FiscalNote stock logo

8. FiscalNote NYSE:NOTE

$0.68 -0.01 (-1.71%)
As of 05/20/2025 03:58 PM Eastern

FiscalNote Holdings, Inc operates as technology company North America, Europe, Australia, and Asia. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. More about FiscalNote

Market Capitalization
$109.44 million
P/E Ratio
-3.08
Consensus Rating
Buy
Consensus Price Target
$2.63 (+288.4% Upside)
Volume
1.57 million shares
Average Volume
1.59 million shares
Clearside Biomedical stock logo

9. Clearside Biomedical NASDAQ:CLSD

$0.88 -0.01 (-1.11%)
As of 05/20/2025 04:00 PM Eastern

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. More about Clearside Biomedical

Market Capitalization
$67.89 million
P/E Ratio
-1.95
Consensus Rating
Buy
Consensus Price Target
$5.00 (+469.2% Upside)
Volume
83,917 shares
Average Volume
345,131 shares
Nektar Therapeutics stock logo

10. Nektar Therapeutics NASDAQ:NKTR

$0.69 -0.01 (-1.14%)
As of 05/20/2025 04:00 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. More about Nektar Therapeutics

Market Capitalization
$127.87 million
P/E Ratio
-0.82
Consensus Rating
Buy
Consensus Price Target
$4.50 (+554.9% Upside)
Volume
1.64 million shares
Average Volume
1.84 million shares
Century Therapeutics stock logo

11. Century Therapeutics NASDAQ:IPSC

$0.60 +0.05 (+8.24%)
As of 05/20/2025 04:00 PM Eastern

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. More about Century Therapeutics

Market Capitalization
$51.70 million
P/E Ratio
-0.32
Consensus Rating
Buy
Consensus Price Target
$4.20 (+600.0% Upside)
Volume
1.64 million shares
Average Volume
469,648 shares
Tenaya Therapeutics stock logo

12. Tenaya Therapeutics NASDAQ:TNYA

$0.48 -0.01 (-2.44%)
As of 05/20/2025 04:00 PM Eastern

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya Therapeutics

Market Capitalization
$77.45 million
P/E Ratio
-0.33
Consensus Rating
Buy
Consensus Price Target
$6.25 (+1,212.7% Upside)
Volume
1.99 million shares
Average Volume
2.45 million shares
Ovid Therapeutics stock logo

13. Ovid Therapeutics NASDAQ:OVID

$0.29 -0.01 (-3.75%)
As of 05/20/2025 04:00 PM Eastern

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid Therapeutics

Market Capitalization
$20.61 million
P/E Ratio
-0.62
Consensus Rating
Buy
Consensus Price Target
$3.03 (+946.7% Upside)
Volume
506,009 shares
Average Volume
465,868 shares
Mersana Therapeutics stock logo

14. Mersana Therapeutics NASDAQ:MRSN

$0.39 +0.01 (+1.30%)
As of 05/20/2025 04:00 PM Eastern

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. More about Mersana Therapeutics

Market Capitalization
$48.61 million
P/E Ratio
-0.64
Consensus Rating
Buy
Consensus Price Target
$5.20 (+1,233.3% Upside)
Volume
2.48 million shares
Average Volume
2.56 million shares
Cognition Therapeutics stock logo

15. Cognition Therapeutics NASDAQ:CGTX

$0.34 +0.01 (+2.48%)
As of 05/20/2025 04:00 PM Eastern

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. More about Cognition Therapeutics

Market Capitalization
$20.46 million
P/E Ratio
-0.35
Consensus Rating
Buy
Consensus Price Target
$6.13 (+1,711.1% Upside)
Volume
438,344 shares
Average Volume
2.60 million shares
Cresco Labs stock logo

16. Cresco Labs OTCMKTS:CRLBF

$0.73 +0.02 (+2.61%)
As of 05/20/2025 03:59 PM Eastern

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. More about Cresco Labs

Market Capitalization
$357.71 million
P/E Ratio
-3.64
Consensus Rating
Buy
Volume
417,249 shares
Average Volume
628,681 shares
Today's Range
$0.68
$0.76
Canaan stock logo

17. Canaan NASDAQ:CAN

$0.76 -0.06 (-7.00%)
As of 05/20/2025 04:00 PM Eastern

Canaan Inc engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. More about Canaan

Market Capitalization
$214.73 million
P/E Ratio
-0.56
Consensus Rating
Moderate Buy
Consensus Price Target
$3.70 (+385.2% Upside)
Volume
38.80 million shares
Average Volume
13.05 million shares
Omega Therapeutics stock logo

18. Omega Therapeutics NASDAQ:OMGA

$0.12 -0.03 (-21.83%)
Closing price 02/24/2025
Extended Trading
$0.12 0.00 (0.00%)
As of 02/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. More about Omega Therapeutics

Market Capitalization
$6.92 million
P/E Ratio
-0.09
Consensus Rating
Moderate Buy
Consensus Price Target
$9.20 (+7,260.0% Upside)
Volume
4.81 million shares
Average Volume
3.08 million shares
Biodesix stock logo

19. Biodesix NASDAQ:BDSX

$0.27 -0.03 (-10.03%)
As of 05/20/2025 04:00 PM Eastern

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. More about Biodesix

Market Capitalization
$39.69 million
P/E Ratio
-0.69
Consensus Rating
Moderate Buy
Consensus Price Target
$2.00 (+638.6% Upside)
Volume
14.13 million shares
Average Volume
787,819 shares
Oncolytics Biotech stock logo

20. Oncolytics Biotech NASDAQ:ONCY

$0.43 -0.01 (-3.35%)
As of 05/20/2025 04:00 PM Eastern

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. More about Oncolytics Biotech

Market Capitalization
$37.14 million
P/E Ratio
-1.59
Consensus Rating
Moderate Buy
Consensus Price Target
$4.33 (+908.5% Upside)
Volume
661,154 shares
Average Volume
531,906 shares
i-80 Gold stock logo

21. i-80 Gold NYSE:IAUX

$0.54 +0.01 (+1.23%)
As of 05/20/2025 04:00 PM Eastern

i-80 Gold Corp. is a mining company, engages in the exploration, development and production of gold and silver mineral deposits principally in the United States. More about i-80 Gold

Market Capitalization
$241.37 million
P/E Ratio
-1.51
Consensus Rating
Moderate Buy
Consensus Price Target
$3.50 (+542.9% Upside)
Volume
5.94 million shares
Average Volume
6.04 million shares
ALX Oncology stock logo

22. ALX Oncology NASDAQ:ALXO

$0.43 0.00 (-0.58%)
As of 05/20/2025 04:00 PM Eastern

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. More about ALX Oncology

Market Capitalization
$22.90 million
P/E Ratio
-0.14
Consensus Rating
Moderate Buy
Consensus Price Target
$3.54 (+725.6% Upside)
Volume
443,235 shares
Average Volume
990,292 shares
Sangamo Therapeutics stock logo

23. Sangamo Therapeutics NASDAQ:SGMO

$0.50 +0.00 (+0.12%)
As of 05/20/2025 04:00 PM Eastern

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. More about Sangamo Therapeutics

Market Capitalization
$116.37 million
P/E Ratio
-0.67
Consensus Rating
Moderate Buy
Consensus Price Target
$4.50 (+801.6% Upside)
Volume
2.99 million shares
Average Volume
8.73 million shares
Adicet Bio stock logo

24. Adicet Bio NASDAQ:ACET

$0.75 +0.04 (+6.19%)
As of 05/20/2025 04:00 PM Eastern

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. More about Adicet Bio

Market Capitalization
$61.98 million
P/E Ratio
-0.44
Consensus Rating
Moderate Buy
Consensus Price Target
$7.50 (+900.8% Upside)
Volume
361,535 shares
Average Volume
727,597 shares
Wag! Group stock logo

25. Wag! Group NASDAQ:PET

$0.15 0.00 (-0.88%)
As of 05/20/2025 04:00 PM Eastern

Wag! Group Co develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. More about Wag! Group

Market Capitalization
$7.47 million
P/E Ratio
-0.37
Consensus Rating
Moderate Buy
Consensus Price Target
$4.13 (+2,727.3% Upside)
Volume
501,564 shares
Average Volume
1.88 million shares